272 related articles for article (PubMed ID: 20203453)
1. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease.
McCullough PA; Verrill TA
Postgrad Med; 2010 Mar; 122(2):25-34. PubMed ID: 20203453
[TBL] [Abstract][Full Text] [Related]
2. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
3. Chronic kidney disease and cardiovascular disease: a case presentation.
McCarley PB; Salai PB
Nephrol Nurs J; 2007; 34(2):187-98; quiz 199-200. PubMed ID: 17486949
[TBL] [Abstract][Full Text] [Related]
4. Micronutrients and cardiorenal disease: insights into novel assessments and treatment.
McCullough PA
Blood Purif; 2011; 31(1-3):177-85. PubMed ID: 21228587
[TBL] [Abstract][Full Text] [Related]
5. [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].
Ravera M; Paoletti E
Ital Heart J Suppl; 2004 Jun; 5(6):436-44. PubMed ID: 15471148
[TBL] [Abstract][Full Text] [Related]
6. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
[TBL] [Abstract][Full Text] [Related]
7. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
Molitch ME
Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
[TBL] [Abstract][Full Text] [Related]
8. Endothelial dysfunction and chronic kidney disease: treatment options.
Wu-Wong JR
Curr Opin Investig Drugs; 2008 Sep; 9(9):970-82. PubMed ID: 18729004
[TBL] [Abstract][Full Text] [Related]
9. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality.
McCullough PA; Li S; Jurkovitz CT; Stevens L; Collins AJ; Chen SC; Norris KC; McFarlane S; Johnson B; Shlipak MG; Obialo CI; Brown WW; Vassalotti J; Whaley-Connell AT; Brenner RM; Bakris GL;
Am Heart J; 2008 Aug; 156(2):277-83. PubMed ID: 18657657
[TBL] [Abstract][Full Text] [Related]
10. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
11. Multiple risk factor intervention in chronic kidney disease: management of cardiac disease in chronic kidney disease patients.
Curtis BM; Levin A; Parfrey PS
Med Clin North Am; 2005 May; 89(3):511-23. PubMed ID: 15755465
[TBL] [Abstract][Full Text] [Related]
12. Addressing cardiovascular disease in patients with renal disease.
Crook ED; Washington DO
Ethn Dis; 2002; 12(4):S3-1-4. PubMed ID: 12477146
[TBL] [Abstract][Full Text] [Related]
13. Optimizing outcomes in patients with cardiovascular disease and chronic kidney disease.
Marrs JC
Am J Manag Care; 2011 Dec; 17 Suppl 15():S403-11. PubMed ID: 22214475
[TBL] [Abstract][Full Text] [Related]
14. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
Weir MR
Postgrad Med; 2009 Jan; 121(1):96-103. PubMed ID: 19179817
[TBL] [Abstract][Full Text] [Related]
15. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease.
McCullough PA; Lepor NE
Rev Cardiovasc Med; 2005; 6 Suppl 3():S4-12. PubMed ID: 16340933
[TBL] [Abstract][Full Text] [Related]
16. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
17. Dyslipidemias in patients who have chronic kidney disease.
Farbakhsh K; Kasiske BL
Med Clin North Am; 2005 May; 89(3):689-99. PubMed ID: 15755473
[TBL] [Abstract][Full Text] [Related]
18. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.
Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
Expert Opin Pharmacother; 2010 Apr; 11(5):723-30. PubMed ID: 20210681
[TBL] [Abstract][Full Text] [Related]
19. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
20. Secondary prevention in concurrent coronary artery, cerebrovascular, and chronic kidney disease: focus on pharmacological therapy.
Notaro LA; Usman MH; Burke JF; Siddiqui A; Superdock KR; Ezekowitz MD
Cardiovasc Ther; 2009; 27(3):199-215. PubMed ID: 19689620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
